MedTrace Logo

Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00003279 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2012-03-06

No results posted yet for this study

Summary

RATIONALE: Vaccines may help the body build an immune response to kill tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of vaccination with monoclonal antibody BEC2 and BCG with that of no further therapy in treating patients who have limited-stage small cell lung cancer.

Conditions

Interventions

BIOLOGICAL

BCG vaccine

BIOLOGICAL

monoclonal antibody BEC2

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Giuseppe Giaccone, MD, PhD · Free University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-03-31
Primary Completion
2000-01-31

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Germany
  • Netherlands
  • New Zealand
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003279 on ClinicalTrials.gov